ACE2 and diabetic kidney disease: In the setting of advanced diabetic nephropathy, where local ACE2 levels are reduced and chronic activation of the RAAS is observed, it is crucial to target endogenous renal ACE2 to achieve optimum therapeutic benefit (Wysocki et al., 2010, 2017).